https://www.selleckchem.com/products/go-203.html
In the AFIRE trial, rivaroxaban monotherapy was noninferior to combination therapy with rivaroxaban and an antiplatelet agent for thromboembolic events or death, and superior for major bleeding in patients with atrial fibrillation (AF) and stable coronary artery disease. Little is known about impacts of stroke and bleeding risks on the efficacy and safety of rivaroxaban monotherapy. In this subanalysis of the AFIRE trial, we assessed the risk of stroke and bleeding by the CHADS , CHA DS -VASc, and HAS-BLED scores. The primary efficacy en
Like
Comment
Share
